

**Beneficiary Advisory Panel Handout  
Uniform Formulary Decisions  
9 January 2013**

**PURPOSE:** The purpose of this handout is to provide BAP Committee members with a reference document for the relative clinical effectiveness presentations for each Uniform Formulary (UF) Class review.

**Table 1: Glucagon-Like Peptide-1 Receptor Agonists**

Formulary Agents:


- Exenatide (Byetta, Bydureon)
- Liraglutide (Victoza)

Nonformulary: None

Step therapy was removed in this subclass

Recommended implementation period: 90 days

**Figure 1: Glucagon-Like Peptide-1 Receptor Agonists  
30-Day Equivalents in All Points of Service**



**Table 2: Overactive Bladder Drugs**

**Formulary:**

Step-preferred: tolterodine ER (Detrol LA), oxybutynin ER, oxybutynin IR


Formulary after a trial of step-preferred agents: trospium (Sanctura IR (gen), Sanctura ER (gen), tolterodine IR, solifenacin (Vesicare)

**Nonformulary after a trial of step-preferred agents:** fesoterodine (Toviaz), darifenacin (Enablex), oxybutynin (Oxytrol patch), oxybutynin (Gelnique 10%)

All patients (current and new users) must receive a trial of the step-preferred agents (No grandfathering)

Implementation Plan: 90 Days

**Figure 2: 30-Day Equivalents in All Points of Service**




**Table 3: Gastrointestinal Oral Antibiotic Drugs (GI-2)**

**Formulary:** metronidazole, vancomycin, neomycin, rifaximin, nitazoxanide, fidaxomicin

**Nonformulary:** None

**Figure 3: Gastrointestinal Oral Antibiotic Drugs (GI-2) Utilization in All Points of Service**



**Table 4:**

**Formulary:** Boceprevir (Victrelis), Interferon alfa-2b (Intron A), PEG-interferon alfa-2a (Pegasys), PEG-interferon alfa-2b (PEG-Intron), Ribavirin (except Ribapak), Telaprevir (Incivek)

**Nonformulary:** Interferon alfacon-1 (Infergen), Ribavirin (Ribapak)

Implementation Plan: 60 Days

**Figure 4: Interferon Utilization in 30-Day Equivalents in All Points of Service**




Figure 5: Ribavirin Utilization in 30-Day Equivalents in All Points of Service





Figure 6: DAA Utilization in 30-Day Equivalents in All Points of Service




**Table 5: Narcotic Analgesics—High Potency**

**Formulary:** Morphine Sulfate (various forms), Codeine tablets, fentanyl patches, hydromorphone various forms, meperidine tablets, oxycodone (Oxycontin), oxymorphone (Opana)

**Nonformulary:** Oxycodone Immediate Release Tablets (Oxecta)

Implementation Plan: 60 Days

**Figure 7: Narcotic Analgesics Utilization in All Points of Service**



**Table 6: Table of Implementation Status of UF Recommendations/Decisions Summary Table**

Meeting	Drug Class	Nonformulary Medications	Total Beneficiaries Affected (# of patients affected)	Beneficiaries Affected by POS			Implementation Plan First Wednesday X days after the decision date	Step Therapy
				MTF	Retail	Mail Order		
Nov 2012	High Potency Narcotics	oxycodone immediate release tablets (Oxecta)	4	0	4	0	60 days	
	Overactive Bladder	fesoterodine (Toviaz),	All agents are currently nonformulary				90 days	tolterodine ER (Detrol LA), oxybutynin ER, oxybutynin IR are step-preferred. ~ 59K will be affected by no grandfathering
		darifenacin (Enablex),						
		oxybutynin (Oxytrol patch),						
		oxybutynin (Gelnique 10%)						
	Hep C	Interferon alfacon-1 (Infergen),	185	5	172	8	60 days	NA
ribavirin (Ribapak )								
								Must try Fortesta products first